Cargando…

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease

Currently, there is a need for diagnostic markers in Lewy body disorders (LBD). α-synuclein (αSyn) RT-QuIC has emerged as a promising assay to detect misfolded αSyn in clinically or neuropathologically established patients with various synucleinopathies. In this study, αSyn RT-QuIC was used to analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Sara, Orrù, Christina D., Serrano, Geidy E., Galasko, Douglas, Hughson, Andrew G., Groveman, Bradley R., Adler, Charles H., Beach, Thomas G., Caughey, Byron, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219141/
https://www.ncbi.nlm.nih.gov/pubmed/35733234
http://dx.doi.org/10.1186/s40478-022-01388-7
_version_ 1784732045299154944
author Hall, Sara
Orrù, Christina D.
Serrano, Geidy E.
Galasko, Douglas
Hughson, Andrew G.
Groveman, Bradley R.
Adler, Charles H.
Beach, Thomas G.
Caughey, Byron
Hansson, Oskar
author_facet Hall, Sara
Orrù, Christina D.
Serrano, Geidy E.
Galasko, Douglas
Hughson, Andrew G.
Groveman, Bradley R.
Adler, Charles H.
Beach, Thomas G.
Caughey, Byron
Hansson, Oskar
author_sort Hall, Sara
collection PubMed
description Currently, there is a need for diagnostic markers in Lewy body disorders (LBD). α-synuclein (αSyn) RT-QuIC has emerged as a promising assay to detect misfolded αSyn in clinically or neuropathologically established patients with various synucleinopathies. In this study, αSyn RT-QuIC was used to analyze lumbar CSF in a clinical cohort from the Swedish BioFINDER study and postmortem ventricular CSF in a neuropathological cohort from the Arizona Study of Aging and Neurodegenerative Disorders/Brain and Body Donation Program (AZSAND/BBDP). The BioFINDER cohort included 64 PD/PDD, 15 MSA, 15 PSP, 47 controls and two controls who later converted to PD/DLB. The neuropathological cohort included 101 cases with different brain disorders, including LBD and controls. In the BioFINDER cohort αSyn RT-QuIC identified LBD (i.e. PD, PDD and converters) vs. controls with a sensitivity of 95% and a specificity of 83%. The two controls that converted to LBD were αSyn RT-QuIC positive. Within the AZSAND/BBDP cohort, αSyn RT-QuIC identified neuropathologically verified "standard LBD" (i.e. PD, PD with AD and DLB; n = 25) vs. no LB pathology (n = 53) with high sensitivity (100%) and specificity (94%). Only 57% were αSyn RT-QuIC positive in the subgroup with "non-standard" LBD (i.e., AD with Lewy Bodies not meeting criteria for DLB or PD, and incidental LBD, n = 23). Furthermore, αSyn RT-QuIC reliably identified cases with LB pathology in the cortex (97% sensitivity) vs. cases with no LBs or LBs present only in the olfactory bulb (93% specificity). However, the sensitivity was low, only 50%, for cases with LB pathology restricted to the brainstem or amygdala, not affecting the allocortex or neocortex. In conclusion, αSyn RT-QuIC of CSF samples is highly sensitive and specific for identifying cases with clinicopathologically-defined Lewy body disorders and shows a lower sensitivity for non-standard LBD or asymptomatic LBD or in cases with modest LB pathology not affecting the cortex. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01388-7.
format Online
Article
Text
id pubmed-9219141
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92191412022-06-24 Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease Hall, Sara Orrù, Christina D. Serrano, Geidy E. Galasko, Douglas Hughson, Andrew G. Groveman, Bradley R. Adler, Charles H. Beach, Thomas G. Caughey, Byron Hansson, Oskar Acta Neuropathol Commun Research Currently, there is a need for diagnostic markers in Lewy body disorders (LBD). α-synuclein (αSyn) RT-QuIC has emerged as a promising assay to detect misfolded αSyn in clinically or neuropathologically established patients with various synucleinopathies. In this study, αSyn RT-QuIC was used to analyze lumbar CSF in a clinical cohort from the Swedish BioFINDER study and postmortem ventricular CSF in a neuropathological cohort from the Arizona Study of Aging and Neurodegenerative Disorders/Brain and Body Donation Program (AZSAND/BBDP). The BioFINDER cohort included 64 PD/PDD, 15 MSA, 15 PSP, 47 controls and two controls who later converted to PD/DLB. The neuropathological cohort included 101 cases with different brain disorders, including LBD and controls. In the BioFINDER cohort αSyn RT-QuIC identified LBD (i.e. PD, PDD and converters) vs. controls with a sensitivity of 95% and a specificity of 83%. The two controls that converted to LBD were αSyn RT-QuIC positive. Within the AZSAND/BBDP cohort, αSyn RT-QuIC identified neuropathologically verified "standard LBD" (i.e. PD, PD with AD and DLB; n = 25) vs. no LB pathology (n = 53) with high sensitivity (100%) and specificity (94%). Only 57% were αSyn RT-QuIC positive in the subgroup with "non-standard" LBD (i.e., AD with Lewy Bodies not meeting criteria for DLB or PD, and incidental LBD, n = 23). Furthermore, αSyn RT-QuIC reliably identified cases with LB pathology in the cortex (97% sensitivity) vs. cases with no LBs or LBs present only in the olfactory bulb (93% specificity). However, the sensitivity was low, only 50%, for cases with LB pathology restricted to the brainstem or amygdala, not affecting the allocortex or neocortex. In conclusion, αSyn RT-QuIC of CSF samples is highly sensitive and specific for identifying cases with clinicopathologically-defined Lewy body disorders and shows a lower sensitivity for non-standard LBD or asymptomatic LBD or in cases with modest LB pathology not affecting the cortex. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-022-01388-7. BioMed Central 2022-06-22 /pmc/articles/PMC9219141/ /pubmed/35733234 http://dx.doi.org/10.1186/s40478-022-01388-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hall, Sara
Orrù, Christina D.
Serrano, Geidy E.
Galasko, Douglas
Hughson, Andrew G.
Groveman, Bradley R.
Adler, Charles H.
Beach, Thomas G.
Caughey, Byron
Hansson, Oskar
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
title Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
title_full Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
title_fullStr Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
title_full_unstemmed Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
title_short Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
title_sort performance of αsynuclein rt-quic in relation to neuropathological staging of lewy body disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219141/
https://www.ncbi.nlm.nih.gov/pubmed/35733234
http://dx.doi.org/10.1186/s40478-022-01388-7
work_keys_str_mv AT hallsara performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT orruchristinad performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT serranogeidye performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT galaskodouglas performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT hughsonandrewg performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT grovemanbradleyr performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT adlercharlesh performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT beachthomasg performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT caugheybyron performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease
AT hanssonoskar performanceofasynucleinrtquicinrelationtoneuropathologicalstagingoflewybodydisease